Company
RELMADA THERAPEUTICS, INC. (RLMD)
Standardized SEC financial data for RELMADA THERAPEUTICS, INC. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001553643 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-66.3%
Free cash flow
-$227.8M
Current ratio
14.62×
EPS (diluted)
$-1.45
Ratios for fiscal year 2012, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| R&D expense | $36.0M | $90.6M | $113.3M | $54.8M | $46.2M | $26.9M |
| SG&A expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.5M | $44.4M | $5.4M | $4.1M | $3.9M | $3.5M |
| Accounts receivable |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$27.8M | -$91.9M | -$103.8M | -$51.7M | -$51.8M | -$45.8M |
| Capital expenditures |
Get RLMD data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/RLMD/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/RLMD/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"